111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
Top Cited Papers
- 12 May 2010
- journal article
- practice guideline
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (7), 1441-1448
- https://doi.org/10.1007/s00259-010-1473-6
Abstract
This document provides general information about somatostatin receptor scintigraphy with 111In-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of 111In-pentetreotide scintigraphy.Keywords
This publication has 38 references indexed in Scilit:
- Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine TumorsAcademic Radiology, 2010
- Attenuation Correction of Somatostatin Receptor SPECT by Integrated Low-Dose CTClinical Nuclear Medicine, 2009
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-PentetreotideNeuroendocrinology, 2009
- Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine TumorsJournal of Clinical Oncology, 2008
- Somatostatin receptor scintigraphy in surveillance of pediatric brain malignanciesPediatric Blood & Cancer, 2008
- Radiolabeled peptides in diagnosis and tumor imaging: Clinical overviewSeminars in Nuclear Medicine, 2002
- Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan)Seminars in Nuclear Medicine, 1995
- Somatostatin Receptor Scintigraphy of Carcinoid Tumours Using the [111In-Dtpa-D-Phe1]-OctreotideActa Oncologica, 1993
- Somatostatin-Receptor Imaging in the Localization of Endocrine TumorsNew England Journal of Medicine, 1990
- Radiation Dose to Patients from RadiopharmaceuticalsAnnals of the ICRP, 1987